A Phase 2 interventional study of Hib-MenCY-TT vaccine and Hib-MenC-TT vaccine in Haemophilus Influenzae Type b and Neisseria Meningitidis, sponsored by GlaxoSmithKline. Completed at 26 sites in 2 countries. Open to participants aged 6 Weeks to 12 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-08-27.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Haemophilus Infections by GlaxoSmithKline — none open to participants now, none under way, none of them phase 3. Haemophilus Infections · GlaxoSmithKline.
Among the 82 studies in Haemophilus Infections by GlaxoSmithKline, this one is the 47th largest by enrollment of the 80 interventional ones that give a count, is one of 7 that started in 2003, is one of 22 in phase 2, and was the 2nd registered.
176 studies on the registry are indexed under Haemophilus Infections; 5 are open to participants now.
Browse Haemophilus Infections studies →None of the 82 studies in Haemophilus Infections by GlaxoSmithKline is open now. The open studies under Haemophilus Infections, anywhere →
Of the 3 Haemophilus Infections studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.
This study: 6 Weeks to 12 Weeks · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 7 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 388 is below the median of 458 across 163 interventional studies indexed under Haemophilus Infections.
Median enrollment 445 across the 80 interventional studies, 270 across the 2 observational. Of the 81 that completed or were terminated, 55 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 82 studies in Haemophilus Infections by GlaxoSmithKline, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluated the safety and immunogenicity of 3 formulations of Hib-MenCY-TT vaccine and 1 formulation of Hib-MenC-TT vaccine compared to a control group receiving licensed meningococcal serogroup C conjugate vaccine, each administered at 2, 3, and 4 months of age. Antibody persistence and immune responses to booster vaccinations were additionally assessed at 12 to 18 months of age.
Primary \& booster vaccination study to evaluate the immuno,reacto \& safety of 3 diff. formulations of GSKBio'combined Haemophilus influenzae typeb-meningococcal serogroups C \& Y-conjugate vaccine \& one formulation of GSKBio' Haemophilus influenzae typeb-meningococcal serogroup C conjugate vaccine each given concomitantly With Infanrix penta (DTaP-IPV-HepB vaccine), vs Meningitec meningococcal SerogroupC conj.vaccine) given concomitantly With Infanrix hexa (DTaP-IPV-HepB-Hib vaccine) in infants according a 2-3-4 mth schedule
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects received Menhibrix vaccine formulation 1 and Infanrix-penta vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menhibrix and Infanrix-penta vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.
Biological: Hib-MenCY-TT vaccine · Biological: Infanrix penta ®
Subjects received Menhibrix vaccine formulation 2 and Infanrix-penta vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menhibrix and Infanrix-penta vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.
Biological: Hib-MenCY-TT vaccine · Biological: Infanrix penta ®
Subjects received Menhibrix vaccine formulation 3 and Infanrix-penta vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menhibrix and Infanrix-penta vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.
Biological: Hib-MenCY-TT vaccine · Biological: Infanrix penta ®
Subjects received Menitorix vaccine and Infanrix-penta vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menitorix and Infanrix-penta vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.
Biological: Hib-MenC-TT vaccine · Biological: Infanrix penta ®
Subjects received Menjugate vaccine and Infanrix-hexa vaccine. Vaccines were administered as a 3-dose primary vaccination course at 2, 3 and 4 months of age (at study Months 0, 1 and 2 of the primary phase). At 12-18 months of age (at study Month 0 of the booster phase), subjects received a booster dose of the two vaccines administered in the primary vaccination course. Menjugate and Infanrix-hexa vaccines were administered intramuscularly in the left and right anterolateral thigh, respectively.
Biological: Menjugate ® · Biological: Infanrix hexa ®
Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.
Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.
Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.
Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in right thigh.
Also known as: DTPa-HBV-IPV vaccine
Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in right thigh.
Also known as: DTPa-HBV-IPV/Hib vaccine
Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration Equal to or Above 1 Microgram Per Millilitre (µg/mL).
Anti-PRP antibody concentration cut-off value assessed was equal to or above (≥) 1 microgram per millilitre (µg/mL)
Time frame: One month after dose 3 (at study Month 3 - primary phase)
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titre Equal to or Above 1:8
rSBA-MenC antibody titre cut-off value assessed was ≥1:8
Time frame: One month after dose 3 (at study Month 3 - primary phase)
Number of Subjects With Meningococcal Serogroup Y Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenY) Titre Equal to or Above 1:8
rSBA-MenY antibody titre cut-off value assessed was ≥1:8
Time frame: One month after dose 3 (at study Month 3 - primary phase)
Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration Equal to or Above 1 Microgram Per Millilitre (µg/mL).
Anti-PRP antibody concentration cut-off value assessed was equal to or above (≥) 1 microgram per millilitre (µg/mL)
Time frame: One month after the booster vaccination (at study Month 1 - booster phase)
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titre Equal to or Above 1:8
rSBA-MenC antibody titre cut-off value assessed was ≥1:8
Time frame: One month after the booster vaccination (at study Month 1 - booster phase)
Number of Subjects With Meningococcal Serogroup Y Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenY) Titre Equal to or Above 1:8
rSBA-MenY antibody titre cut-off value assessed was ≥1:8
Time frame: One month after the booster vaccination (at study Month 1 - booster phase)
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titre Equal to or Above 1:8
rSBA-MenC antibody titre cut-off value assessed was ≥1:8
Time frame: Before the administration of the first dose (at pre-vaccination = study Month 0 - primary phase)
Number of Subjects With Meningococcal Serogroup Y Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenY) Titre Equal to or Above 1:8
rSBA-MenY antibody titre cut-off value assessed was ≥1:8
Time frame: Before the administration of the first dose (at pre-vaccination = study Month 0 - primary phase)
Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration Equal to or Above 1 Microgram Per Millilitre (µg/mL).
Anti-PRP antibody concentration cut-off value assessed was equal to or above (≥) 1 microgram per millilitre (µg/mL)
Time frame: Before the administration of the first dose (at pre-vaccination = study Month 0 - primary phase)
Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration Equal to or Above 1 Microgram Per Millilitre (µg/mL).
Anti-PRP antibody concentration cut-off value assessed was equal to or above (≥) 1 microgram per millilitre (µg/mL)
Time frame: Prior to the booster vaccination (at study Month 0 - booster phase)
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titre Equal to or Above 1:8
rSBA-MenC antibody titre cut-off value assessed was ≥1:8
Time frame: Prior to the booster vaccination (at study Month 0 - booster phase)
Number of Subjects With Meningococcal Serogroup Y Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenY) Titre Equal to or Above 1:8
rSBA-MenY antibody titre cut-off value assessed was ≥1:8
Time frame: Prior to the booster vaccination (at study Month 0 - booster phase)
rSBA-MenC Antibody Titres
Titres are expressed as geometric mean titres (GMTs)
Time frame: Prior to the first dose and one month after the third dose (at study Months 0 and 3 - primary phase)
rSBA-MenY Antibody Titres
Titres are expressed as geometric mean titres (GMTs)
Time frame: Prior to the first dose and one month after the third dose (at study Months 0 and 3 - primary phase)
Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration Equal to or Above 0.15 Microgram Per Millilitre (µg/mL).
Anti-PRP antibody concentration cut-off value assessed was equal to or above (≥) 0.15 microgram per millilitre (µg/mL)
Time frame: Prior to the first dose and one month after the third dose (at study Months 0 and 3 - primary phase)
Anti-PRP Antibody Concentrations
Antibody concentrations are expressed as geometric mean concentrations (GMCs) in µg/mL.
Time frame: Prior to the first dose and one month after the third dose (at study Months 0 and 3 - primary phase)
Number of Subjects With Anti-polysaccharide C (Anti-PSC) Antibody Concentration Equal to or Above 0.30 Microgram Per Millilitre (µg/mL)
Anti-PSC antibody concentration cut-off value assessed was ≥0.30 µg/mL
Time frame: Prior to the first dose and one month after the third dose (at study Months 0 and 3 - primary phase)
Number of Subjects With Anti-polysaccharide Y (Anti-PSY) Antibody Concentration Equal to or Above 0.30 Microgram Per Millilitre (µg/mL)
Anti-PSY antibody concentration cut-off value assessed was ≥0.30 µg/mL
Time frame: Prior to the first dose and one month after the third dose (at study Months 0 and 3 - primary phase)
Anti-PSC Antibody Concentrations
Antibody concentrations are expressed as geometric mean concentrations (GMCs) in µg/mL.
Time frame: Prior to the first dose and one month after the third dose (at study Months 0 and 3 - primary phase)
Anti-PSY Antibody Concentrations
Antibody concentrations are expressed as geometric mean concentrations (GMCs) in µg/mL.
Time frame: Prior to the first dose and one month after the third dose (at study Months 0 and 3 - primary phase)
Anti-tetanus Antibody Concentrations
Antibody concentrations are expressed as geometric mean concentrations (GMCs) in International Units per millilitre (IU/mL).
Time frame: Prior to the first dose and one month after the third dose (at study Months 0 and 3 - primary phase)
Anti-filamentous Haemagglutinin (Anti-FHA), Anti-pertactin (Anti-PRN), Anti-pertussis Toxoid (Anti-PT) Antibody Concentrations
Antibody concentrations are expressed as geometric mean concentrations (GMCs) in Enzyme-Linked Immunosorbent Assay (ELISA) Units per millilitre.
Time frame: Prior to the first dose and one month after the third dose (at study Months 0 and 3 - primary phase)
Number of Seroprotected Subjects for Anti-tetanus Antibodies
Seroprotection status is defined as anti-tetanus toxoid antibody concentration ≥ 0.1 International Units per millilitre (IU/mL)
Time frame: Prior to the first dose and one month after the third dose (at study Months 0 and 3 - primary phase)
Number of Subjects With Anti-FHA, Anti-PRN and Anti-PT Antibody Concentration Equal to or Above 5 Enzyme-Linked Immunosorbent Assay (ELISA) Units Per Millilitre (EL.U/mL)
Anti-FHA, anti-PRN and anti-PT antibody concentration cut-off value assessed was ≥ 5 ELISA units per millilitre.
Time frame: Prior to the first dose and one month after the third dose (at study Months 0 and 3 - primary phase)
Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration Equal to or Above 0.15 Microgram Per Millilitre (µg/mL).
Anti-PRP antibody concentration cut-off value assessed was equal to or above (≥) 0.15 microgram per millilitre (µg/mL)
Time frame: Prior to and one month post booster vaccination (at study Months 0 and 1 - booster phase)
Anti-PRP Antibody Concentrations
Antibody concentrations are expressed as geometric mean concentrations (GMCs) in µg/mL.
Time frame: Prior to and one month post booster vaccination (at study Months 0 and 1 - booster phase)
Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titre Equal to or Above 1:128
rSBA-MenC antibody titre cut-off value assessed was ≥1:128
Time frame: Prior to and one month post booster vaccination (at study Months 0 and 1 - booster phase)
Number of Subjects With Meningococcal Serogroup Y Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenY) Titre Equal to or Above 1:128
rSBA-MenY antibody titre cut-off value assessed was ≥1:128
Time frame: Prior to and one month post booster vaccination (at study Months 0 and 1 - booster phase)
rSBA-MenC Antibody Titres
Titres are expressed as geometric mean titres (GMTs)
Time frame: Prior to and one month post booster vaccination (at study Months 0 and 1 - booster phase)
rSBA-MenY Antibody Titres
Titres are expressed as geometric mean titres (GMTs)
Time frame: Prior to and one month post booster vaccination (at study Months 0 and 1 - booster phase)
Number of Subjects With Anti-polysaccharide C (Anti-PSC) Antibody Concentration Equal to or Above 0.30 Microgram Per Millilitre (µg/mL)
Anti-PSC antibody concentration cut-off value assessed was ≥0.30 µg/mL
Time frame: Prior to and one month post booster vaccination (at study Months 0 and 1 - booster phase)
Number of Subjects With Anti-polysaccharide C (Anti-PSC) Antibody Concentration Equal to or Above 2.0 Microgram Per Millilitre (µg/mL)
Anti-PSC antibody concentration cut-off value assessed was ≥2.0 µg/mL
Time frame: Prior to and one month post booster vaccination (at study Months 0 and 1 - booster phase)
Anti-PSC Antibody Concentrations
Antibody concentrations are expressed as geometric mean concentrations (GMCs) in µg/mL.
Time frame: Prior to and one month post booster vaccination (at study Months 0 and 1 - booster phase)
Anti-PSY Antibody Concentrations
Antibody concentrations are expressed as geometric mean concentrations (GMCs) in µg/mL.
Time frame: Prior to and one month post booster vaccination (at study Months 0 and 1 - booster phase)
Number of Subjects With Anti-tetanus Toxoid (Anti-T) Antibody Concentration Equal to or Above 0.1 International Units Per Millilitre (IU/mL).
Anti-tetanus toxoid antibody concentration cut-off value assessed was ≥ 0.1 IU/mL
Time frame: Prior to and one month post booster vaccination (at study Months 0 and 1 - booster phase)
Anti-T Antibody Concentrations
Antibody concentrations are expressed as geometric mean concentrations (GMCs) in International Units per millilitre (IU/mL).
Time frame: Prior to and one month post booster vaccination (at study Months 0 and 1 - booster phase)
Anti-diphtheria Antibody Concentrations
Antibody concentrations are expressed as geometric mean concentrations (GMCs) in IU/mL.
Time frame: One month after the third dose (at study Month 3 - primary phase)
Anti-hepatitis B Surface Antigen (HBs) Antibody Concentrations
Antibody concentrations are expressed as geometric mean concentrations (GMCs) in milli-International Units per millilitre (mIU/mL).
Time frame: One month after the third dose (at study Month 3 - primary phase)
Anti-poliovirus Types 1, 2, 3 Antibody Titres
Titres are expressed as geometric mean titres (GMTs)
Time frame: One month after the third dose (at study Month 3 - primary phase)
Number of Seroprotected Subjects for Anti-diphtheria Antibodies
Seroprotection status is defined as anti-diphtheria antibody concentrations ≥ 0.1 IU/mL
Time frame: One month after the third dose (at study Month 3 - primary phase)
Number of Seroprotected Subjects for Anti-hepatitis B Antibodies
Seroprotection status is defined as anti-HBs antibody concentrations ≥ 10 mIU/mL
Time frame: One month after the third dose (at study Month 3 - primary phase)
Number of Seroprotected Subjects for Anti-poliovirus Types 1, 2 and 3 Antibodies
Seroprotection status is defined as anti-polio 1, 2 and 3 antibody titres ≥ 1:8
Time frame: One month after the third dose (at study Month 3 - primary phase)
Number of Subjects With Vaccine Response to PT, FHA and PRN
Vaccine response rates are defined as appearance of antibodies in subjects who were initially seronegative (i.e., with concentrations \< cut-off value) or at least maintenance of pre-vaccination antibody concentrations in subjects who were initially seropositive (i.e., with concentrations ≥ cut-off value), taking into consideration the decreasing maternal antibodies.
Time frame: One month after the third dose (at study Month 3 - primary phase)
Number of Subjects With Solicited Local Symptoms
Solicited local symptoms assessed were pain, redness and swelling.
Time frame: During the 8-day (Day 0-7) follow-up period (during the primary phase)
Number of Subjects With Solicited General Symptoms
Solicited general symptoms assessed were drowsiness, irritability, loss of appetite and fever (fever is defined as rectal temperature ≥ 38.0 degrees Celsius (°C)).
Time frame: During the 8-day (Day 0-7) follow-up period (during the primary phase)
Number of Subjects With Unsolicited Adverse Events (AEs)
An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Time frame: During the 31-day (Day 0-30) follow-up period (during the primary phase)
Number of Subjects Reporting Serious Adverse Events (SAEs)
SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.
Time frame: Over the full course of the primary phase (up to study Month 3 - primary phase)
Number of Subjects With Solicited Local Symptoms
Solicited local symptoms assessed were pain, redness and swelling.
Time frame: During the 8-day (Day 0-7) follow-up period (during the booster phase)
Number of Subjects With Solicited General Symptoms
Solicited general symptoms assessed were drowsiness, irritability, loss of appetite and fever (fever is defined as rectal temperature ≥ 38.0 degrees Celsius (°C)).
Time frame: During the 8-day (Day 0-7) follow-up period (during the booster phase)
Number of Subjects With Unsolicited Adverse Events (AEs)
An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
Time frame: During the 31-day (Day 0-30) follow-up period (during the booster phase)
Number of Subjects Reporting Serious Adverse Events (SAEs)
SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.
Time frame: Over the full course of the booster phase (up to study Month 1 - booster phase)
| Milestone | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Started | 78 | 77 | 78 | 78 | 77 |
| Completed | 76 | 73 | 77 | 77 | 76 |
| Not completed | 2 | 4 | 1 | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 | 1 | 1 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 1 | 0 | 0 |
| Milestone | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Started | 47 | 42 | 44 | 44 | 44 |
| Completed | 45 | 42 | 44 | 44 | 43 |
| Not completed | 2 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 2 | 0 | 0 | 0 | 1 |
Anti-PRP antibody concentration cut-off value assessed was equal to or above (≥) 1 microgram per millilitre (µg/mL)
| Subjects | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration Equal to or Above 1 Microgram Per Millilitre (µg/mL). | 66 | 66 | 69 | 73 | 57 |
rSBA-MenC antibody titre cut-off value assessed was ≥1:8
| Subjects | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titre Equal to or Above 1:8 | 70 | 67 | 71 | 74 | 71 |
rSBA-MenY antibody titre cut-off value assessed was ≥1:8
| Subjects | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Number of Subjects With Meningococcal Serogroup Y Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenY) Titre Equal to or Above 1:8 | 67 | 64 | 70 | 16 | 14 |
Anti-PRP antibody concentration cut-off value assessed was equal to or above (≥) 1 microgram per millilitre (µg/mL)
| Subjects | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration Equal to or Above 1 Microgram Per Millilitre (µg/mL). | 39 | 39 | 39 | 40 | 39 |
rSBA-MenC antibody titre cut-off value assessed was ≥1:8
| Subjects | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titre Equal to or Above 1:8 | 40 | 39 | 42 | 41 | 39 |
rSBA-MenY antibody titre cut-off value assessed was ≥1:8
| Subjects | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Number of Subjects With Meningococcal Serogroup Y Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenY) Titre Equal to or Above 1:8 | 40 | 39 | 42 | 13 | 14 |
rSBA-MenC antibody titre cut-off value assessed was ≥1:8
| Subjects | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titre Equal to or Above 1:8 | 4 | 6 | 4 | 6 | 3 |
rSBA-MenY antibody titre cut-off value assessed was ≥1:8
| Subjects | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Number of Subjects With Meningococcal Serogroup Y Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenY) Titre Equal to or Above 1:8 | 11 | 10 | 16 | 10 | 17 |
Anti-PRP antibody concentration cut-off value assessed was equal to or above (≥) 1 microgram per millilitre (µg/mL)
| Subjects | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration Equal to or Above 1 Microgram Per Millilitre (µg/mL). | 13 | 8 | 8 | 9 | 3 |
Anti-PRP antibody concentration cut-off value assessed was equal to or above (≥) 1 microgram per millilitre (µg/mL)
| Subjects | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Number of Subjects With Anti-polyribosyl-ribitol Phosphate (Anti-PRP) Antibody Concentration Equal to or Above 1 Microgram Per Millilitre (µg/mL). | 26 | 28 | 27 | 32 | 11 |
rSBA-MenC antibody titre cut-off value assessed was ≥1:8
| Subjects | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Number of Subjects With Meningococcal Serogroup C Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenC) Titre Equal to or Above 1:8 | 38 | 38 | 38 | 39 | 36 |
rSBA-MenY antibody titre cut-off value assessed was ≥1:8
| Subjects | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Number of Subjects With Meningococcal Serogroup Y Serum Bactericidal Assay Using Rabbit Complement (rSBA-MenY) Titre Equal to or Above 1:8 | 35 | 31 | 36 | 11 | 15 |
Titres are expressed as geometric mean titres (GMTs)
| Titers | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| rSBA-MenC [Month 0] (N=69,64,70,73,71) | 4.7 (3.9 to 5.7) | 4.8 (4.1 to 5.6) | 4.6 (4.0 to 5.4) | 4.7 (4.0 to 5.7) | 4.5 (3.9 to 5.2) |
| rSBA-MenC [Month 3] (N=70,67,71,74,71) | 1005.8 (773.5 to 1308.0) | 1029.8 (799.7 to 1326.0) | 906.9 (691.3 to 1189.8) | 871.0 (677.3 to 1120.0) | 3557.6 (2978.8 to 4248.8) |
Titres are expressed as geometric mean titres (GMTs)
| Titers | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| rSBA-MenY [Month 0] (N=70,63,71,73,71) | 5.9 (4.7 to 7.5) | 5.9 (4.6 to 7.6) | 7.4 (5.6 to 9.9) | 5.9 (4.6 to 7.4) | 7.7 (5.7 to 10.3) |
| rSBA-MenY [Month 3] (N=69,66,71,74,71) | 470.7 (351.1 to 631.2) | 437.1 (322.0 to 593.4) | 635.3 (501.5 to 804.8) | 9.3 (6.3 to 13.7) | 7.5 (5.4 to 10.4) |
Anti-PRP antibody concentration cut-off value assessed was equal to or above (≥) 0.15 microgram per millilitre (µg/mL)
| Subjects | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Anti-PRP >= 0.15 µg/mL [Mth 0] (N=69,63,71,73,71) | 51 | 42 | 50 | 50 | 50 |
| Anti-PRP >= 0.15 µg/mL [Mth 3] (N=67,67,70,74,71) | 67 | 67 | 70 | 74 | 71 |
Antibody concentrations are expressed as geometric mean concentrations (GMCs) in µg/mL.
| µg/mL | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Anti-PRP [Month 0] (N=69,63,71,73,71) | 0.289 (0.217 to 0.385) | 0.243 (0.185 to 0.318) | 0.255 (0.197 to 0.331) | 0.243 (0.184 to 0.319) | 0.217 (0.177 to 0.267) |
| Anti-PRP [Month 3] (N=67,67,70,74,71) | 9.014 (7.248 to 11.209) | 9.485 (7.721 to 11.651) | 8.075 (6.532 to 9.982) | 10.435 (8.487 to 12.830) | 2.595 (1.965 to 3.428) |
Anti-PSC antibody concentration cut-off value assessed was ≥0.30 µg/mL
| Subjects | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Anti-PSC [Month 0] (N=69,63,71,74,71) | 7 | 12 | 7 | 7 | 10 |
| Anti-PSC [Month 3] (N=69,66,70,74,71) | 69 | 66 | 70 | 74 | 71 |
Anti-PSY antibody concentration cut-off value assessed was ≥0.30 µg/mL
| Subjects | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Anti-PSY [Month 0] (N=69,64,71,73,71) | 7 | 6 | 12 | 15 | 12 |
| Anti-PSY [Month 3] (N=69,66,70,74,71) | 69 | 66 | 70 | 6 | 4 |
Antibody concentrations are expressed as geometric mean concentrations (GMCs) in µg/mL.
| µg/mL | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Anti-PSC [Month 0] (N=69,63,71,74,71) | 0.18 (0.16 to 0.20) | 0.20 (0.17 to 0.24) | 0.18 (0.16 to 0.21) | 0.18 (0.15 to 0.22) | 0.18 (0.16 to 0.21) |
| Anti-PSC [Month 3] (N=69,66,70,74,71) | 21.70 (18.36 to 25.65) | 27.26 (23.26 to 31.95) | 19.02 (16.49 to 21.93) | 21.08 (18.24 to 24.35) | 38.49 (33.64 to 44.05) |
Antibody concentrations are expressed as geometric mean concentrations (GMCs) in µg/mL.
| µg/mL | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Anti-PSY [Month 0] (N=69,64,71,73,71) | 0.19 (0.16 to 0.23) | 0.18 (0.15 to 0.20) | 0.20 (0.17 to 0.25) | 0.22 (0.18 to 0.27) | 0.20 (0.17 to 0.23) |
| Anti-PSY [Month 3] (N=69,66,70,74,71) | 26.86 (22.86 to 31.56) | 37.02 (31.84 to 43.04) | 23.57 (19.94 to 27.86) | 0.19 (0.15 to 0.25) | 0.17 (0.15 to 0.19) |
Antibody concentrations are expressed as geometric mean concentrations (GMCs) in International Units per millilitre (IU/mL).
| IU/mL | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Anti-tetanus [Month 0] (N=69,63,71,73,71) | 0.433 (0.320 to 0.586) | 0.485 (0.373 to 0.630) | 0.523 (0.388 to 0.705) | 0.436 (0.323 to 0.589) | 0.379 (0.285 to 0.503) |
| Anti-tetanus [Month 3] (N=68,67,70,74,71) | 3.057 (2.629 to 3.554) | 3.254 (2.879 to 3.677) | 2.972 (2.591 to 3.409) | 3.151 (2.726 to 3.641) | 1.656 (1.394 to 1.967) |
Antibody concentrations are expressed as geometric mean concentrations (GMCs) in Enzyme-Linked Immunosorbent Assay (ELISA) Units per millilitre.
| EL.U/mL | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Anti-PT [Month 0] (N=67,62,68,70,69) | 3.4 (2.9 to 4.0) | 3.1 (2.7 to 3.5) | 3.7 (3.0 to 4.6) | 3.3 (2.8 to 4.0) | 3.1 (2.7 to 3.5) |
| Anti-PT [Month 3] (N=67,63,69,74,69) | 53.9 (46.3 to 62.7) | 52.9 (45.3 to 61.8) | 50.8 (44.1 to 58.5) | 55.4 (48.1 to 63.7) | 41.3 (35.1 to 48.5) |
| Anti-FHA [Month 0] (N=69,63,69,72,70) | 6.5 (5.2 to 8.1) | 6.0 (4.8 to 7.5) | 7.3 (5.7 to 9.3) | 9.9 (7.8 to 12.6) | 7.0 (5.6 to 8.7) |
| Anti-FHA [Month 3] (N=67,63,69,74,71) | 83.7 (72.9 to 96.0) | 91.5 (78.7 to 106.3) | 89.3 (78.4 to 101.6) | 92.4 (79.8 to 106.9) | 74.0 (64.9 to 84.5) |
| Anti-PRN [Month 0] (N=68,62,71,72,70) | 6.3 (4.9 to 8.2) | 4.5 (3.6 to 5.7) | 5.5 (4.5 to 6.8) | 6.4 (4.9 to 8.3) | 6.5 (5.0 to 8.4) |
| Anti-PRN [Month 3] (N=68,67,70,74,71) | 94.2 (77.6 to 114.5) | 97.1 (79.8 to 118.2) | 96.2 (80.2 to 115.5) | 99.1 (79.0 to 124.3) | 80.2 (66.1 to 97.2) |
Seroprotection status is defined as anti-tetanus toxoid antibody concentration ≥ 0.1 International Units per millilitre (IU/mL)
| Subjects | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Anti-tetanus [Month 0] (N=69,63,71,73,71) | 58 | 57 | 60 | 63 | 61 |
| Anti-tetanus [Month 3] (N=68,67,70,74,71) | 68 | 67 | 70 | 74 | 71 |
Anti-FHA, anti-PRN and anti-PT antibody concentration cut-off value assessed was ≥ 5 ELISA units per millilitre.
| Subjects | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Anti-PT [Month 0] (N=67,62,68,70,69) | 15 | 11 | 18 | 12 | 9 |
| Anti-PT [Month 3] (N=67,63,69,74,69) | 67 | 63 | 69 | 74 | 69 |
| Anti-FHA [Month 0] (N=69,63,69,72,70) | 42 | 37 | 42 | 55 | 45 |
| Anti-FHA [Month 3] (N=67,63,69,74,71) | 67 | 63 | 69 | 74 | 71 |
| Anti-PRN [Month 0] (N=68,62,71,72,70) | 36 | 25 | 37 | 37 | 37 |
| Anti-PRN [Month 3] (N=68,67,70,74,71) | 68 | 67 | 70 | 74 | 71 |
Anti-PRP antibody concentration cut-off value assessed was equal to or above (≥) 0.15 microgram per millilitre (µg/mL)
| Subjects | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Anti-PRP >= 0.15 µg/mL Month 0 (N=41,39,42,42,36) | 39 | 38 | 42 | 42 | 36 |
| Anti-PRP >= 0.15 µg/mL Month 1 (N=39,39,39,40,39) | 39 | 39 | 39 | 40 | 39 |
Antibody concentrations are expressed as geometric mean concentrations (GMCs) in µg/mL.
| µg/mL | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Anti-PRP [Month 0] (N=41,39,42,42,36) | 1.306 (0.947 to 1.801) | 1.591 (1.185 to 2.135) | 1.414 (1.068 to 1.871) | 1.764 (1.301 to 2.391) | 0.607 (0.459 to 0.802) |
| Anti-PRP [Month 1] (N=39,39,39,40,39) | 36.280 (27.856 to 47.252) | 32.930 (22.797 to 47.567) | 34.107 (24.902 to 46.715) | 47.742 (34.631 to 65.817) | 24.345 (17.445 to 33.974) |
rSBA-MenC antibody titre cut-off value assessed was ≥1:128
| Subjects | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| rSBA-Menc [Month 0] (N=42,39,41,41,38) | 25 | 24 | 22 | 27 | 26 |
| rSBA-Menc [Month 1] (N=40,39,42,41,39) | 40 | 36 | 42 | 40 | 39 |
rSBA-MenY antibody titre cut-off value assessed was ≥1:128
| Subjects | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| rSBA-MenY [Month 0] (N=41,39,42,42,37) | 24 | 18 | 23 | 6 | 7 |
| rSBA-MenY [Month 1] (N=40,39,42,40,39) | 40 | 39 | 42 | 6 | 10 |
Titres are expressed as geometric mean titres (GMTs)
| Titers | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| rSBA-MenC [Month 0] (N=42,39,41,41,38) | 128.0 (74.9 to 218.5) | 144.2 (92.8 to 224.1) | 125.8 (81.0 to 195.3) | 150.6 (96.7 to 234.5) | 195.5 (122.4 to 312.2) |
| rSBA-MenC [Month 1] (N=40,39,42,41,39) | 4762.6 (3427.5 to 6617.7) | 2897.7 (1793.1 to 4682.7) | 2626.4 (1893.9 to 3642.3) | 3226.2 (2294.7 to 4535.8) | 11819.3 (8458.6 to 16515.2) |
Titres are expressed as geometric mean titres (GMTs)
| Titres | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| rSBA-MenY [Month 0] (N=41,39,42,42,37) | 97.2 (58.4 to 161.8) | 64.0 (37.6 to 108.9) | 100.9 (62.3 to 163.5) | 11.0 (6.3 to 19.1) | 16.1 (8.8 to 29.5) |
| rSBA-MenY [Month 1] (N=40,39,42,40,39) | 1708.1 (1313.3 to 2221.4) | 1313.8 (1004.4 to 1718.6) | 1566.0 (1172.8 to 2091.1) | 11.7 (6.8 to 20.2) | 16.5 (8.7 to 31.3) |
Anti-PSC antibody concentration cut-off value assessed was ≥0.30 µg/mL
| Subjects | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Anti-PSC [Month 0] (N=38,38,40,40,38) | 38 | 38 | 40 | 40 | 38 |
| Anti-PSC [Month 1] (N=33,33,39,37,39) | 33 | 33 | 39 | 37 | 39 |
Anti-PSC antibody concentration cut-off value assessed was ≥2.0 µg/mL
| Subjects | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Anti-PSC [Month 0] (N=38,38,40,40,38) | 24 | 30 | 28 | 26 | 27 |
| Anti-PSC [Month 1] (N=33,33,39,37,39) | 33 | 33 | 39 | 37 | 39 |
Antibody concentrations are expressed as geometric mean concentrations (GMCs) in µg/mL.
| µg/mL | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Anti-PSC [Month 0] (N=38,38,40,40,38) | 2.57 (1.88 to 3.51) | 3.23 (2.55 to 4.08) | 2.53 (2.06 to 3.12) | 3.08 (2.33 to 4.08) | 3.17 (2.46 to 4.08) |
| Anti-PSC [Month 1] (N=33,33,39,37,39) | 32.04 (22.99 to 44.65) | 28.00 (19.40 to 40.42) | 19.75 (15.23 to 25.60) | 27.71 (22.23 to 34.54) | 64.41 (50.72 to 81.79) |
Antibody concentrations are expressed as geometric mean concentrations (GMCs) in µg/mL.
| µg/mL | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Anti-PSY [Month 0] (N=39,39,42,42,38) | 3.72 (2.76 to 5.03) | 5.25 (3.95 to 6.96) | 3.96 (3.02 to 5.19) | 0.16 (0.14 to 0.19) | NA (NA to NA) |
| Anti-PSY [Month 1] (N=42,39,41,40,38) | 26.15 (17.80 to 38.42) | 35.90 (25.33 to 50.88) | 32.18 (25.26 to 40.99) | 0.17 (0.13 to 0.21) | NA (NA to NA) |
Anti-tetanus toxoid antibody concentration cut-off value assessed was ≥ 0.1 IU/mL
| Subjects | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Anti-tetanus [Month 0] (N=41,39,42,42,38) | 41 | 39 | 42 | 42 | 37 |
| Anti-tetanus [Month 1] (N=39,39,39,40,39) | 39 | 39 | 39 | 40 | 39 |
Antibody concentrations are expressed as geometric mean concentrations (GMCs) in International Units per millilitre (IU/mL).
| IU/mL | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Anti-tetanus [Month 0] (N=41,39,42,42,38) | 0.836 (0.655 to 1.067) | 0.986 (0.810 to 1.202) | 0.894 (0.748 to 1.069) | 0.839 (0.693 to 1.016) | 0.322 (0.257 to 0.402) |
| Anti-tetanus [Month 1] (N=39,39,39,40,39) | 12.609 (10.769 to 14.762) | 10.175 (8.269 to 12.520) | 9.893 (8.255 to 11.856) | 11.674 (9.538 to 14.288) | 5.474 (4.331 to 6.918) |
Antibody concentrations are expressed as geometric mean concentrations (GMCs) in IU/mL.
| IU/mL | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Anti-diphtheria Antibody Concentrations | 1.016 (0.796 to 1.297) | 0.927 (0.759 to 1.132) | 0.980 (0.788 to 1.219) | 1.012 (0.827 to 1.238) | 1.904 (1.606 to 2.258) |
Antibody concentrations are expressed as geometric mean concentrations (GMCs) in milli-International Units per millilitre (mIU/mL).
| mIU/mL | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Anti-hepatitis B Surface Antigen (HBs) Antibody Concentrations | 377.9 (261.7 to 545.8) | 397.0 (271.5 to 580.4) | 408.9 (305.9 to 546.6) | 520.5 (374.1 to 724.3) | 287.3 (194.3 to 424.7) |
Titres are expressed as geometric mean titres (GMTs)
| Titers | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Anti-poliovirus type 1 (N=57,55,56,61,56) | 275.5 (206.9 to 366.8) | 242.0 (181.2 to 323.4) | 216.8 (162.6 to 288.9) | 305.2 (229.2 to 406.4) | 282.6 (204.4 to 390.7) |
| Anti-poliovirus type 2 (N=55,55,58,61,56) | 155.8 (110.4 to 220.0) | 149.9 (108.3 to 207.7) | 133.7 (95.5 to 187.2) | 123.1 (86.3 to 175.6) | 171.3 (123.2 to 238.1) |
| Anti-poliovirus type 3 (N=57,55,58,61,56) | 649.0 (492.3 to 855.7) | 577.2 (418.7 to 795.8) | 451.7 (320.9 to 635.9) | 603.6 (452.7 to 804.6) | 505.7 (375.5 to 681.0) |
Seroprotection status is defined as anti-diphtheria antibody concentrations ≥ 0.1 IU/mL
| Subjects | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Number of Seroprotected Subjects for Anti-diphtheria Antibodies | 66 | 64 | 69 | 74 | 69 |
Seroprotection status is defined as anti-HBs antibody concentrations ≥ 10 mIU/mL
| Subjects | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Number of Seroprotected Subjects for Anti-hepatitis B Antibodies | 60 | 60 | 66 | 70 | 61 |
Seroprotection status is defined as anti-polio 1, 2 and 3 antibody titres ≥ 1:8
| Subjects | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Anti-poliovirus type 1 (N=57,55,56,61,56) | 57 | 55 | 56 | 61 | 55 |
| Anti-poliovirus type 2 (N=55,55,58,61,56) | 55 | 55 | 58 | 59 | 56 |
| Anti-poliovirus type 3 (N=57,55,58,61,56) | 57 | 55 | 58 | 61 | 56 |
Vaccine response rates are defined as appearance of antibodies in subjects who were initially seronegative (i.e., with concentrations \< cut-off value) or at least maintenance of pre-vaccination antibody concentrations in subjects who were initially seropositive (i.e., with concentrations ≥ cut-off value), taking into consideration the decreasing maternal antibodies.
| Subjects | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Anti-PT (N=64,58,66,70,68) | 63 | 58 | 64 | 66 | 68 |
| Anti-FHA (N=66,59,67,72,70) | 65 | 58 | 65 | 68 | 70 |
| Anti-PRN (N=66,62,70,72,70) | 61 | 59 | 68 | 63 | 65 |
Solicited local symptoms assessed were pain, redness and swelling.
| Subjects | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Pain | 21 | 20 | 22 | 19 | 19 |
| Redness | 35 | 38 | 50 | 32 | 46 |
| Swelling | 31 | 35 | 30 | 27 | 35 |
Solicited general symptoms assessed were drowsiness, irritability, loss of appetite and fever (fever is defined as rectal temperature ≥ 38.0 degrees Celsius (°C)).
| Subjects | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Drowsiness | 39 | 53 | 43 | 37 | 46 |
| Irritability | 44 | 42 | 51 | 47 | 44 |
| Loss of appetite | 24 | 34 | 29 | 33 | 30 |
| Fever (rectal) >= 38.0°C | 25 | 28 | 26 | 28 | 28 |
An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
| Subjects | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Number of Subjects With Unsolicited Adverse Events (AEs) | 39 | 33 | 35 | 31 | 26 |
SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.
| Subjects | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Number of Subjects Reporting Serious Adverse Events (SAEs) | 0 | 1 | 2 | 1 | 3 |
Solicited local symptoms assessed were pain, redness and swelling.
| Subjects | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Pain | 5 | 10 | 8 | 8 | 9 |
| Redness | 20 | 18 | 22 | 16 | 16 |
| Swelling | 15 | 12 | 12 | 9 | 10 |
Solicited general symptoms assessed were drowsiness, irritability, loss of appetite and fever (fever is defined as rectal temperature ≥ 38.0 degrees Celsius (°C)).
| Subjects | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Drowsiness | 14 | 18 | 18 | 17 | 18 |
| Irritability | 16 | 18 | 19 | 14 | 17 |
| Loss of appetite | 11 | 16 | 12 | 10 | 14 |
| Fever (rectal) >= 38.0°C | 13 | 10 | 16 | 18 | 16 |
An unsolicited adverse event is any adverse event (i.e. any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with use of a medicinal product, whether or not considered related to the medicinal product) reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.
| Subjects | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Number of Subjects With Unsolicited Adverse Events (AEs) | 7 | 12 | 13 | 12 | 11 |
SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects.
| Subjects | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Number of Subjects Reporting Serious Adverse Events (SAEs) | 1 | 1 | 0 | 1 | 0 |
Collected over SAEs: Over the full course of the primary and booster phases (up to Month 3 - primary phase and up to Month 1 - booster phase). Unsolicited AEs: During the 31-day (Days 0-30) follow-up period. Solicited AEs: During the 8-day (Days 0-7) follow-up period. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Menhibrix F1/Infanrix-penta Group | — | 1/78 (1.3%) | 70/78 (89.7%) |
| Menhibrix F2/Infanrix-penta Group | — | 1/77 (1.3%) | 71/77 (92.2%) |
| Menhibrix F3/Infanrix-penta Group | — | 2/78 (2.6%) | 73/78 (93.6%) |
| Menitorix/Infanrix-penta Group | — | 1/78 (1.3%) | 71/78 (91%) |
| Menjugate/Infanrix-hexa Group | — | 3/77 (3.9%) | 70/77 (90.9%) |
| Event | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| Febrile convulsionNervous system disorders | 0/47 | 1/42 | 0/44 | 0/44 | 0/44 |
| Upper respiratory tract infectionInfections and infestations | 0/47 | 1/42 | 0/44 | 0/44 | 0/44 |
| Otitis mediaInfections and infestations | 0/47 | 0/42 | 0/44 | 1/44 | 0/44 |
| GastroenteritisInfections and infestations | 1/47 | 0/42 | 0/44 | 0/44 | 0/44 |
| ApnoeaRespiratory, thoracic and mediastinal disorders | 0/78 | 0/77 | 0/78 | 0/78 | 1/77 |
| BronchitisInfections and infestations | 0/78 | 0/77 | 0/78 | 0/78 | 1/77 |
| DehydrationMetabolism and nutrition disorders | 0/78 | 0/77 | 0/78 | 0/78 | 1/77 |
| GastroenteritisInfections and infestations | 0/78 | 0/77 | 0/78 | 0/78 | 1/77 |
| Laryngotracheo bronchitisInfections and infestations | 0/78 | 0/77 | 0/78 | 0/78 | 1/77 |
| Urinary tract infectionInfections and infestations | 0/78 | 1/77 | 0/78 | 0/78 | 0/77 |
| Event | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group |
|---|---|---|---|---|---|
| DrowsinessGeneral disorders | 39/78 | 53/77 | 43/78 | 37/78 | 46/77 |
| IrritabilityGeneral disorders | 44/78 | 42/77 | 51/78 | 47/78 | 44/77 |
| RednessGeneral disorders | 35/78 | 38/77 | 50/78 | 32/78 | 46/77 |
| RednessGeneral disorders | 20/47 | 18/42 | 22/44 | 16/44 | 16/44 |
| SwellingGeneral disorders | 31/78 | 35/77 | 30/78 | 27/78 | 35/77 |
| Loss of appetiteGeneral disorders | 24/78 | 34/77 | 29/78 | 33/78 | 30/77 |
| IrritabilityGeneral disorders | 16/47 | 18/42 | 19/44 | 14/44 | 17/44 |
| DrowsinessGeneral disorders | 14/47 | 18/42 | 18/44 | 17/44 | 18/44 |
| FeverGeneral disorders | 13/47 | 10/42 | 16/44 | 18/44 | 16/44 |
| Loss of appetiteGeneral disorders | 11/47 | 16/42 | 12/44 | 10/44 | 14/44 |
| Age, Continuous(Weeks) | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group | Total |
|---|---|---|---|---|---|---|
| Mean | 8.5 ± 1.69 | 8.8 ± 1.72 | 8.7 ± 1.55 | 8.3 ± 1.63 | 9.0 ± 1.65 | 8.7 ± 1.65 |
| Sex: Female, Male(Participants) | Menhibrix F1/Infanrix-penta Group | Menhibrix F2/Infanrix-penta Group | Menhibrix F3/Infanrix-penta Group | Menitorix/Infanrix-penta Group | Menjugate/Infanrix-hexa Group | Total |
|---|---|---|---|---|---|---|
| Female | 31 | 37 | 44 | 33 | 40 | 185 |
| Male | 47 | 40 | 34 | 45 | 37 | 203 |
Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
The record gives a start of Mar 2003, a primary completion of Dec 2003 and a completion of Dec 2003. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2012, 8 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Hib-MenCY-TT vaccine · Pediarix